RxDoctor Payments Data

Michelle Thomas

Family · Detroit, MINPI 1306994090

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,265 of the $36,146 with a category attached, or 64.4%. Gilead accounts for 96.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $13,773, 4.9 times the $2,798 reported in 2021. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,146in general payments, 2019–2025

Across 262 payments — averaging $137.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$35K
  • Viiv Healthcare Company$500
  • AbbVie$159
  • Merck$151
  • Genentech USA, Inc.$125
  • Janssen Products, LP$99
  • plus $384 from 8 others

What the payments were for

  • Consulting fees$1,3204%
  • Speaking & faculty fees$23,26564%
  • Travel & lodging$6,44418%
  • Food & beverage$4,99014%
  • Education$1270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,146 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala83$327,048
SerostimSomatropin13$264,618
GenvoyaElviteg/Cob/Emtri/Tenof Alafen65$257,531
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf48$218,674
OdefseyEmtricitab/Rilpiviri/Tenof Ala49$169,162
RukobiaFostemsavir Tromethamine16$139,998
CabenuvaCabotegravir/Rilpivirine17$113,234
DovatoDolutegravir Sodium/Lamivudine38$111,006
TivicayDolutegravir Sodium43$91,621
JulucaDolutegravir/Rilpivirine22$82,734
DescovyEmtricitabine/Tenofov Alafenam37$80,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$79,668
EliquisApixaban59$36,587
PrezcobixDarunavir/Cobicistat12$27,637
TrulicityDulaglutide21$23,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$34,728$664,772185 claims
Viiv Healthcare CompanyRukobia, Cabenuva, Dovato, Tivicay, Juluca$500$538,593136 claims
Janssen Products, LPSymtuza$99$218,67448 claims
GSKTrelegy Ellipta, Incruse Ellipta$28$87,738140 claims
Johnson & JohnsonPrezcobix$42$27,63712 claims
AbbVieCreon$159$13,28112 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$38$53660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →